Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26257742 | 0.85 | SLC6A2 (0.33) | RAPGEF3SLC6A2SLC6A4SLC6A3PDE2A | |
| SCHEMBL26965588 | 0.83 | RAPGEF3 (0.35) | RAPGEF3HTTALDH1A1 | |
| SCHEMBL30786553 | 0.83 | RAPGEF3 (0.35) | RAPGEF3HTTALDH1A1 | |
| SCHEMBL26965578 | 0.81 | PKM (0.33) | — | |
| SCHEMBL29154736 | 0.76 | AKR1C3 (0.36) | RAPGEF3HTTMEN1ALDH1A1KMT2A | |
| SCHEMBL25401676 | 0.75 | MIF (0.46) | — | |
| SCHEMBL26965563 | 0.73 | AR (0.31) | — | |
| SCHEMBL530151 | 0.67 | HTT (0.42) | RAPGEF3HTTMEN1ALDH1A1MAPT | |
| SCHEMBL13930880 | 0.65 | TSHR (0.40) | HTTMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13933403 | 0.65 | NPC1 (0.42) | HTTMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | disclosed |
| CN-119278197-A | Imidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030856-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | RAPGEF3 2078/4885SLC6A2 269/4885SLC6A4 629/4885 |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | RAPGEF3 1794/4885SLC6A2 291/4885SLC6A4 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.